Franklyn G. Prendergast - 02 Oct 2023 Form 4 Insider Report for Immunome Inc. (IMNM)

Role
Director
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Issuer symbol
IMNM
Transactions as of
02 Oct 2023
Net transactions value
+$185,929
Form type
4
Filing time
04 Oct 2023, 17:28:38 UTC
Previous filing
12 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMNM Common Stock Award $0 +60,840 $0.000000 60,840 02 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMNM Stock Option (Right to Buy) Award $185,929 +137,725 $1.35* 137,725 02 Oct 2023 Common Stock 137,725 $1.35 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the Closing (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by an among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.), Dr. Prendergast exchanged (i) his shares of common stock of Morphimmune for shares of the Issuer and (ii) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.
F2 In connection with the Closing (as defined in the Merger Agreement), all the shares underlying the option became fully vested and exercisable.